הפעלת התכווצות אבי העורקים רוחבית עם תפר נספג להשגת היפרטרופיה שריר הלב ארעית

Executive Industry Relevance

This protocol enables reliable induction and regression of transient myocardial hypertrophy in murine models, supporting mechanistic studies of cardiac remodeling and hypertrophy regression. By reducing surgical complexity and mortality, it improves reproducibility and scalability for preclinical target validation in cardiovascular drug discovery. The model facilitates de-risking of therapeutic hypotheses related to myocardial preconditioning and reversible remodeling pathways.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in myocardial hypertrophy regression and preconditioning mechanisms.
• Operational Value: Reduces technical barriers and mortality, improving model accessibility for target validation studies.

Screening & Assay Development

• Scientific Value: Provides a standardized, quantifiable model for assessing compound effects on hypertrophic signaling and reverse remodeling.
• Operational Value: Supports assay readiness through reproducible induction and timed regression of hypertrophy using absorbable sutures.

Translational & Preclinical Research

• Scientific Value: Models disease-relevant transient hypertrophy to evaluate therapeutic impact on cardiomyocyte size and function.
• Operational Value: Enables longitudinal assessment of hypertrophy progression and regression, supporting risk-adjusted advancement decisions.

Pipeline & Workflow Integration

The method fits within the cardiovascular discovery continuum from target validation through preclinical efficacy testing, particularly for compounds targeting hypertrophic pathways.

• Discovery Biology: Supports mechanistic de-risking by modeling pressure-overload hypertrophy and its regression to clarify target engagement and pathway modulation.
• Screening: Delivers quantitative echocardiographic outputs (LV wall thickness, dimensions, fractional shortening) for compound screening and dose-response assessment.
• Analytics: Generates measurable hemodynamic and histological endpoints (pressure gradient, wall thickness, cardiomyocyte cross-sectional area) to enable comparative analysis across conditions.
• Translational Research: Connects early hypertrophy induction to preclinical validation of regression phenotypes, aligning with therapeutic strategies for heart failure.
• Enterprise Reuse: Establishes a reusable surgical platform for iterative testing of cardioprotective or anti-hypertrophic agents across discovery campaigns.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by modeling reversible hypertrophy, reducing ambiguity in target mechanism interpretation.
• Operational Value: Improves standardization and survival rates, increasing throughput and reducing variability in preclinical studies.
• Strategic Value: Supports better go/no-go decisions by enabling early assessment of hypertrophy regression potential, mitigating late-stage biological risk.
• Portfolio Impact: Facilitates risk-adjusted prioritization of compounds demonstrating efficacy in both induction and reversal of hypertrophic phenotypes.

Implementation Considerations

• Requires expertise in murine cardiac surgery and echocardiographic imaging.
• Dependent on micro-surgical instruments, ultrasound systems with 30 MHz probes, and sterile field maintenance.
• Necessitates cross-team standardization of surgical timing, anesthesia depth, and imaging protocols for reproducible results.
• Adaptation considerations include model suitability across mouse strains and comorbidities affecting cardiac response to pressure overload.
• Practical limitations include operator-dependent suture placement consistency and the need for vigilant monitoring to avoid pleural damage and pneumothorax.

Biopharma FAQs